Intendis: Mid-Sized Specialist Spawns Small Specialist
Executive Summary
In dermatology offshoot Intendis, Schering AG has created the ideal European crossbreed: a group with the management experience associated with spin-outs, and a revenue-generating side more typical of specialty pharma. The snag: Schering's retaining full ownership--for now.
You may also be interested in...
Bayer And Kythera Strike Licensing Deal in Aesthetic Dermatology
Bayer's Intendis skin care unit bets on a niche drug that is likely to depend on out-of-pocket payments.
Deep-Pocketed Big Pharma Meets Spec Pharma's Challenge
In early 2006, we noted in this space that in-licensing on the part of specialty pharmaceutical start-ups was rising relative to Big Pharma's in-licensing rate, with specialty pharmas even out-competing Big Pharma in some specific cases for rights to promising clinical programs. Since then, however, Big Pharma's unprecedented late-stage spending spree has far outpaced spec pharma's licensing, particularly in clinical stage deals.
Deep-Pocketed Big Pharma Meets Spec Pharma's Challenge
In early 2006, we noted in this space that in-licensing on the part of specialty pharmaceutical start-ups was rising relative to Big Pharma's in-licensing rate, with specialty pharmas even out-competing Big Pharma in some specific cases for rights to promising clinical programs. Since then, however, Big Pharma's unprecedented late-stage spending spree has far outpaced spec pharma's licensing, particularly in clinical stage deals.